This $295,700 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel inhaled combination therapy by Parion Sciences, Inc. for the treatment of muco-obstructive lung diseases such as COPD and asthma.
The key products and services to be delivered through this 1-year grant include: 1) formulation and stability studies for a next-generation ENaC blocker (P-1155) drug candidate, 2) efficacy evaluation of the P-1155/osmolyte combination in a muco-obstructive mouse model, 3) development of an aerosol delivery formulation, 4) ADME/PK studies, and 5) a 28-day GLP inhalation toxicology study. The overall goal is to advance this combination therapy to Investigational New Drug (IND) status for the treatment of COPD. As a development-stage biopharmaceutical company, Parion Sciences has expertise in restoring lung mucosal defenses and creating innovative therapeutics for chronic respiratory conditions.
Generated 3/4/25, 4:46 AM